Published in Biotech Business Week, March 7th, 2005
The multicenter Canadian study was led by Derek Exner, MD, University of Calgary Associate professor of Medicine, Libin Cardiovascular Institute of Alberta.
The study enrolled individuals who had experienced a recent myocardial infarction or heart attack. The patients also had impaired pumping efficiency of the heart as determined by an ejection fraction of 50% or less. All patients were being treated with optimal medical therapy.
In addition to Microvolt T-Wave...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.